What the study found
Forty-two people with migraine were randomized to CoQ10 or placebo in a double-blind study. Investigators compared attack frequency, headache days and days with nausea. [1]
Those outcomes favored CoQ10 in the third treatment month. The reported proportion with at least a halving of attack frequency was higher with CoQ10, but the sample was small. [1]
What remains unanswered
A preventive endpoint after repeated use cannot establish an immediate rescue effect. The trial also does not prove which biological pathway caused the observed difference or guarantee an individual response. Funding and conflicts were not established from the abstract. [1]
A hypothetical distinction
Imagine a person has fewer attacks over a later month. That differs from showing that a capsule stops an attack within minutes; the two questions require different trial designs.
| Detail | Interpretation |
|---|---|
| 42 people | Small trial |
| Third month | Preventive assessment |
| Acute rescue | Not tested |
Sources for this article
- Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial - PubMed
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.